Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We are analyzing https://www.nature.com/articles/s41392-020-0204-0.

Title:
IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas | Signal Transduction and Targeted Therapy
Description:
The insulin-like growth factor 1 receptor (IGF-1R) governs several signaling pathways for cell proliferation, survival, and anti-apoptosis. Thus, targeting IGF-1R appears as a reasonable rationale for tumor treatment. However, clinical studies showed that inhibition of IGF-1R has very limited efficacy due to the development of resistance to IGF-1R blockade in tumor cells. Here, we discovered that prolonged treatment of colon cancer cells with IGF-1R inhibitors (BMS-754807 and GSK1838705A) stimulates p70 KDa ribosomal protein S6 kinase 1 (p70S6K1) activation, a well-known kinase signaling for cell survival. We also found that p70S6K1 activation by IGF-1R inhibition is independent of K-Ras and PIK3CA mutations that frequently occur in colon cancer. Besides the increased p70S6K1 phosphorylation, the phosphorylation of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) was elevated in the cells treated with BMS-754807. Interestingly, the increases in MEK1/2 and p70S6K1 phosphorylation were also observed when cells were subjected to the treatment of AKT inhibitor or genetic knockdown of AKT2 but not AKT1, suggesting that AKT2 inhibition stimulates MEK1/2 phosphorylation to activate p70S6K1. Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor (U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating mutual inhibition between AKT and MEK. Furthermore, the combination of BMS-754807 and U0126 efficiently decreased the cell viability and increased cleaved caspase 3 and apoptosis in vitro and in vivo. Our data suggest that the treatment of colon tumor cells with IGF-1R inhibitors stimulates p70S6K1 activity via MEK1/2 to promote survival, providing a new strategy for colorectal cancer therapeutics.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$536,300 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $357,503 to $983,134.

Keywords {🔍}

psk, cells, phosphorylation, bms, mek, igfr, akt, fig, inhibition, cell, treated, pubmed, cancer, pdcd, activation, google, scholar, inhibitor, tumor, cas, colon, translation, data, protein, treatment, increased, knockdown, shown, hct, growth, survival, activity, mice, osi, analyzed, mrna, kinase, erk, significantly, western, central, resistance, independent, nature, levels, blot, images, induces, proliferation, inhibitors,

Topics {✒️}

nature portfolio privacy policy nature advertising social media dual igf-ir/ir inhibitor a-raf-related protein phosphorylation reprints p70 s6-kinase mediates igf-1r-mediated activation real-time quantitative pcr igf-1r governs pi3k/akt igf-1r signaling pathway targeting igf-1r appears artificial stem-loop structure hsin-sheng yang overcoming igf1r/ir resistance potent igf-1r inhibitor igf-1r/ir inhibitor full size image igf-ir null cells growth factor-1r/ir anti-igf-1r agents represses p53-dependent apoptosis phospho-s6 ribosomal protein antibodies targeting igf-1r markey cancer center author correspondence original author permissions phospho-p-70s6k1/gapdh igf-1r expression levels colon cancer therapy ras/erk signaling pathways ribosome-bound rnas igf-1r inhibition results inhibits pro-apoptotic proteins stress-induced kinases inhibits p53-dependent apoptosis pathogen-free conditions bms-754807-induced p70s6k1 activation dead box helicases kras mutation testing krasg12c inhibitors mediated china authors china academy development promotes cell death pro-apoptotic molecule bad ribosomal protein s6

Questions {❓}

  • How does MEK activate AKT?
  • If it is through IGF-1R inhibition, what is the molecular mechanism to induce p70S6K1 activation?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas
         description:The insulin-like growth factor 1 receptor (IGF-1R) governs several signaling pathways for cell proliferation, survival, and anti-apoptosis. Thus, targeting IGF-1R appears as a reasonable rationale for tumor treatment. However, clinical studies showed that inhibition of IGF-1R has very limited efficacy due to the development of resistance to IGF-1R blockade in tumor cells. Here, we discovered that prolonged treatment of colon cancer cells with IGF-1R inhibitors (BMS-754807 and GSK1838705A) stimulates p70 KDa ribosomal protein S6 kinase 1 (p70S6K1) activation, a well-known kinase signaling for cell survival. We also found that p70S6K1 activation by IGF-1R inhibition is independent of K-Ras and PIK3CA mutations that frequently occur in colon cancer. Besides the increased p70S6K1 phosphorylation, the phosphorylation of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) was elevated in the cells treated with BMS-754807. Interestingly, the increases in MEK1/2 and p70S6K1 phosphorylation were also observed when cells were subjected to the treatment of AKT inhibitor or genetic knockdown of AKT2 but not AKT1, suggesting that AKT2 inhibition stimulates MEK1/2 phosphorylation to activate p70S6K1. Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor (U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating mutual inhibition between AKT and MEK. Furthermore, the combination of BMS-754807 and U0126 efficiently decreased the cell viability and increased cleaved caspase 3 and apoptosis in vitro and in vivo. Our data suggest that the treatment of colon tumor cells with IGF-1R inhibitors stimulates p70S6K1 activity via MEK1/2 to promote survival, providing a new strategy for colorectal cancer therapeutics.
         datePublished:2020-08-26T00:00:00Z
         dateModified:2020-08-26T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1038/s41392-020-0204-0
         keywords:
            Cancer therapy
            Gastrointestinal cancer
            Medicine/Public Health
            general
            Internal Medicine
            Cancer Research
            Cell Biology
            Pathology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig8_HTML.png
         isPartOf:
            name:Signal Transduction and Targeted Therapy
            issn:
               2059-3635
            volumeNumber:5
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Qing Wang
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yan Zhang
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jiang Zhu
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
                     name:Qilu Hospital of Shandong University
                     address:
                        name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
                     name:Qilu Hospital of Shandong University
                     address:
                        name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Honggang Zheng
               affiliation:
                     name:China Academy of Chinese Medical Sciences
                     address:
                        name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shuntai Chen
               affiliation:
                     name:China Academy of Chinese Medical Sciences
                     address:
                        name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Li Chen
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hsin-Sheng Yang
               affiliation:
                     name:University of Kentucky
                     address:
                        name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
                     name:University of Kentucky
                     address:
                        name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas
      description:The insulin-like growth factor 1 receptor (IGF-1R) governs several signaling pathways for cell proliferation, survival, and anti-apoptosis. Thus, targeting IGF-1R appears as a reasonable rationale for tumor treatment. However, clinical studies showed that inhibition of IGF-1R has very limited efficacy due to the development of resistance to IGF-1R blockade in tumor cells. Here, we discovered that prolonged treatment of colon cancer cells with IGF-1R inhibitors (BMS-754807 and GSK1838705A) stimulates p70 KDa ribosomal protein S6 kinase 1 (p70S6K1) activation, a well-known kinase signaling for cell survival. We also found that p70S6K1 activation by IGF-1R inhibition is independent of K-Ras and PIK3CA mutations that frequently occur in colon cancer. Besides the increased p70S6K1 phosphorylation, the phosphorylation of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) was elevated in the cells treated with BMS-754807. Interestingly, the increases in MEK1/2 and p70S6K1 phosphorylation were also observed when cells were subjected to the treatment of AKT inhibitor or genetic knockdown of AKT2 but not AKT1, suggesting that AKT2 inhibition stimulates MEK1/2 phosphorylation to activate p70S6K1. Conversely, inhibition of MEK1/2 by MEK1/2 inhibitor (U0126) or knockdown of MEK1 and MEK2 by corresponding mek1 and mek2 siRNA enhanced AKT phosphorylation, indicating mutual inhibition between AKT and MEK. Furthermore, the combination of BMS-754807 and U0126 efficiently decreased the cell viability and increased cleaved caspase 3 and apoptosis in vitro and in vivo. Our data suggest that the treatment of colon tumor cells with IGF-1R inhibitors stimulates p70S6K1 activity via MEK1/2 to promote survival, providing a new strategy for colorectal cancer therapeutics.
      datePublished:2020-08-26T00:00:00Z
      dateModified:2020-08-26T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1038/s41392-020-0204-0
      keywords:
         Cancer therapy
         Gastrointestinal cancer
         Medicine/Public Health
         general
         Internal Medicine
         Cancer Research
         Cell Biology
         Pathology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41392-020-0204-0/MediaObjects/41392_2020_204_Fig8_HTML.png
      isPartOf:
         name:Signal Transduction and Targeted Therapy
         issn:
            2059-3635
         volumeNumber:5
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Qing Wang
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yan Zhang
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jiang Zhu
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
                  name:Qilu Hospital of Shandong University
                  address:
                     name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
                  name:Qilu Hospital of Shandong University
                  address:
                     name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Honggang Zheng
            affiliation:
                  name:China Academy of Chinese Medical Sciences
                  address:
                     name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shuntai Chen
            affiliation:
                  name:China Academy of Chinese Medical Sciences
                  address:
                     name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Li Chen
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hsin-Sheng Yang
            affiliation:
                  name:University of Kentucky
                  address:
                     name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
                  name:University of Kentucky
                  address:
                     name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Signal Transduction and Targeted Therapy
      issn:
         2059-3635
      volumeNumber:5
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Kentucky
      address:
         name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:Qilu Hospital of Shandong University
      address:
         name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
         type:PostalAddress
      name:Qilu Hospital of Shandong University
      address:
         name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
         type:PostalAddress
      name:China Academy of Chinese Medical Sciences
      address:
         name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
         type:PostalAddress
      name:China Academy of Chinese Medical Sciences
      address:
         name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
         type:PostalAddress
      name:University of Kentucky
      address:
         name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Qing Wang
      affiliation:
            name:University of Kentucky
            address:
               name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Yan Zhang
      affiliation:
            name:University of Kentucky
            address:
               name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Jiang Zhu
      affiliation:
            name:University of Kentucky
            address:
               name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
            name:Qilu Hospital of Shandong University
            address:
               name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
            name:Qilu Hospital of Shandong University
            address:
               name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
               type:PostalAddress
            type:Organization
      name:Honggang Zheng
      affiliation:
            name:China Academy of Chinese Medical Sciences
            address:
               name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
               type:PostalAddress
            type:Organization
      name:Shuntai Chen
      affiliation:
            name:China Academy of Chinese Medical Sciences
            address:
               name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
               type:PostalAddress
            type:Organization
      name:Li Chen
      affiliation:
            name:University of Kentucky
            address:
               name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      name:Hsin-Sheng Yang
      affiliation:
            name:University of Kentucky
            address:
               name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
            name:University of Kentucky
            address:
               name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
      name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
      name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
      name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
      name:Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, China
      name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
      name:Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
      name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA
      name:Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, USA
      name:Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, USA

External Links {🔗}(127)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

4.15s.